Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Open accessPublished version of a preprint
Abstract
BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sotrovimab remained active against the Omicron spike, consistent with sotrovimab recognizing an epitope not substantially altered by mutations found in the Omicron spike.
“sotrovimab, a pan-sarbecovirus-neutralizing antibody (Gupta et al., 2021), remained active against the Omicron spike, in keeping with sotrovimab recognizing an epitope not substantially altered by mutations found in the Omicron spike”
From The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2022) · cites this paper as Gupta et al., 2021
The antibody sotrovimab was shown to inhibit SARS-CoV-2 and related viruses and to protect patients from COVID-19.
“the antibody sotrovimab was shown to inhibit SARS-CoV-2 and related viruses and was found to protect patients from COVID-19”
From The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2022) · cites this paper as Gupta et al., 2021
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079 · see citing works
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045 · see citing works
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278 · see citing works
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642 · see citing works
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387 · see citing works
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282 · see citing works
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al‐Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05180-x · Cited by 820 · see citing works
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 657 · see citing works
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485 · see citing works
Self-citationStarr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470 · see citing works
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S., Pegu, A., Rudicell, R. S., Yang, Z., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Räth, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384 · see citing works
Group sequential designs using a family of type I error probability spending functions
Hwang, I. K., Shih, W. J., & de Cani, J. S. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091207 · Cited by 247 · see citing works
Gaudinski, M. R., Coates, E. E., Houser, K. V., Chen, G. L., Yamshchikov, G. V., Saunders, J. G., Holman, L. A., Gordon, I. J., Plummer, S. H., Hendel, C. S., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002493 · Cited by 241 · see citing works
Cathcart, A. L., Havenar‐Daughton, C., Lempp, F. A., Ma, D., Schmid, M., Agostini, M. L., Guarino, B., di Iulio, J., Rosen, L. E., Tucker, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434607 · Cited by 206 · see citing works
Self-citationReese, H. E., Iuliano, A. D., Patel, N. N., Garg, S., Kim, L., Silk, B. J., Hall, A. J., Fry, A. M., & Reed, C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1780 · Cited by 181 · see citing works
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 148 · see citing works
Angulo, F. J., Finelli, L., & Swerdlow, D. L. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33706 · Cited by 131 · see citing works
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Preprint
McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437925 · Cited by 128 · see citing works
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S. W., Reynoso, L., Downey, G. P., Frankel, S. K., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1919285 · Cited by 87 · see citing works
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Liu, H.-L., Wei, P., Zhang, Q.-Q., et al. (2021) · bioRxiv · doi:10.1101/2021.02.16.431305 · Cited by 80 · see citing works
Tada, T., Dcosta, B. M., Zhou, H., Vaill, A., Kazmierski, W., & Landau, N. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.18.431897 · Cited by 59 · see citing works
Lempp, F., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y.-J., Bianchi, S., Walls, A., Bowen, J., Zhou, J.-Y., et al. (2021) · bioRxiv · doi:10.1101/2021.04.03.438258 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323 · see citing works
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857 · see citing works
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb, R., Vaca, C., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2116846 · Cited by 1,230 · see citing works
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,043 · see citing works
Self-citationThe biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · see citing works
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889 · see citing works
VanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 676 · see citing works
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
Junqueira, C., Crespo, Â. C., Ranjbar, S., de Lacerda, L., Lewandrowski, M., Ingber, J., Parry, B. A., Ravid, S., Clark, S. A., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 669 · see citing works
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630 · see citing works
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A., et al. (2022) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 498 · see citing works
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 495 · see citing works
Self-citationGruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410 · see citing works
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 398 · see citing works
Pan, H., Peto, R., Restrepo, A. M. H., Préziosi, M., Moorthy, V., Karim, Q. A., Alejandria, M., García, C. H., Kiény, M.-P., Malekzadeh, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00519-0 · Cited by 392 · see citing works
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 375 · see citing works
Kaplon, H., Chenoweth, A. M., Crescioli, S., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2021.2014296 · Cited by 330 · see citing works
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04778-y · Cited by 297 · see citing works
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Lempp, F. A., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y., Bianchi, S., Walls, A. C., Bowen, J. E., Zhou, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03925-1 · Cited by 292 · see citing works
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łoś, M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100794 · Cited by 292 · see citing works
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B. M., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119657 · Cited by 287 · see citing works
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B. E., Fenwick, C. W., Joo, V., & Perez, L. H. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 286 · see citing works
Gupta, A. K., Gonzalez‐Rojas, Y., Juarez, E., Casal, M. C., Moya, J., Falci, D. R., Sarkis, E. H., Solis, J., Zheng, H., Scott, N. E., et al. (2022) · JAMA · doi:10.1001/jama.2022.2832 · Cited by 270 · see citing works
Self-citationSARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity
Pilz, S., Theiler‐Schwetz, V., Trummer, C., Krause, R. G. E., & Ioannidis, J. P. A. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112911 · Cited by 262 · see citing works
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S. A., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 262 · see citing works
Shah, M., & Woo, H. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.830527 · Cited by 248 · see citing works
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 247 · see citing works
Self-citationMontgomery, H., Hobbs, R. F., Padilla, F., Arbetter, D. F., Templeton, A., Seegobin, S., Kim, K., Campos, J. A. S., Arends, R. H., Brodek, B. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00180-1 · Cited by 218 · see citing works
Loo, Y.-M., McTamney, P. M., Arends, R., Abram, M. E., Aksyuk, A., Diallo, S., Flores, D. J., Kelly, E. J., Ren, K.-S., Roque, R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl8124 · Cited by 194 · see citing works
Mucosal immune response in biology, disease prevention and treatment
Zhou, X., Wu, Y., Zhu, Z., Lu, C., Zhang, C., Zeng, L., Xie, F., Zhang, L., & Zhou, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02043-4 · Cited by 217 · see citing works
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Baden, L. R., Cheng, V. C., Edwards, K. M., Gallagher, J. C., Gandhi, R. T., Muller, W. J., Nakamura, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac724 · Cited by 215 · see citing works
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 205 · see citing works
Self, W. H., Sandkovsky, U., Reilly, C. S., Vock, D. M., Gottlieb, R. L., Mack, M., Golden, K., Dishner, E., Vekstein, A., Ko, E. R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00751-9 · Cited by 200 · see citing works
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
Planas, D., Bruel, T., Staropoli, I., Guivel‐Benhassine, F., Porrot, F., Maes, P., Grzelak, L., Prot, M., Mougari, S., Planchais, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36561-6 · Cited by 190 · see citing works
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188 · see citing works
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Grainger, R., Kim, A. H. J., Conway, R. P., Yazdany, J., & Robinson, P. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00755-x · Cited by 185 · see citing works
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
Rockett, R. J., Basile, K., Maddocks, S., Fong, W., Agius, J. E., Johnson-Mackinnon, J., Arnott, A., Chandra, S., Gall, M., Draper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2120219 · Cited by 171 · see citing works
Shan, S., Luo, S., Yang, Z., Hong, J., Su, Y., Ding, F., Fu, L., Li, C., Chen, P., Ma, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122954119 · Cited by 157 · see citing works
COVID-19 therapeutics: Challenges and directions for the future
Robinson, P. C., Liew, D. F. L., Tanner, H. L., Grainger, J. R., Dwek, R. A., Reisler, R. B., Steinman, L., Feldmann, M., Ho, L., Hussell, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119893119 · Cited by 156 · see citing works
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Sakaguchi, H., Sonoyama, T., Ichihashi, G., Sanaki, T., Baba, K., Tsuge, Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac933 · Cited by 153 · see citing works
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 152 · see citing works
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Kreuzberger, N., Hirsch, C., Chai, K. L., Tomlinson, E., Khosravi, Z., Popp, M., Neidhardt, M., Piechotta, V., Salomon, S., Valk, S. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013825.pub2 · Cited by 149 · see citing works
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
Karoui, K. E., & Vriese, A. S. D. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.022 · Cited by 145 · see citing works
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works
Lewnard, J. A., McLaughlin, J. M., Malden, D. E., Hong, V. X., Puzniak, L., Ackerson, B. K., Lewin, B. J., Kim, J. S., Shaw, S. F., Takhar, H. S., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00118-4 · Cited by 146 · see citing works
Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 142 · see citing works
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 141 · see citing works
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 140 · see citing works
Neutralising antibodies predict protection from severe COVID-19
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139 · see citing works
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139 · see citing works
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00697-22 · Cited by 137 · see citing works
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 136 · see citing works
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J., & Landau, N. R. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103944 · Cited by 132 · see citing works
SARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 132 · see citing works
Holland, T. L., Ginde, A. A., Paredes, R., Murray, T. A., Engen, N. W., Grandits, G., Vekstein, A. M., Ivey, N., Mourad, A., Sandkovsky, U., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00215-6 · Cited by 122 · see citing works
Cesaro, S., Ljungman, P. T., Mikulska, M., Hirsch, H. H., von Lilienfeld‐Toal, M., Cordonnier, C., Meylan, S., Mehra, V., Styczyński, J., Marchesi, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01578-1 · Cited by 118 · see citing works
Hunt, A. C., Case, J. B., Park, Y., Cao, L., Wu, K., Walls, A. C., Liu, Z., Bowen, J. E., Yeh, A. H.-W., Saini, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1252 · Cited by 116 · see citing works
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
Edwards, A. M., Baric, R. S., Saphire, E. O., & Ulmer, J. B. (2022) · Science · doi:10.1126/science.abn1900 · Cited by 107 · see citing works
Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H., Jagannathan, P., & Shafer, R. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 72 · see citing works
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Nimmo, A., Gardiner, D. D., Ushiro‐Lumb, I., Ravanan, R., & Forsythe, J. L. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004151 · Cited by 104 · see citing works
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Kumar, S., Chandele, A., & Sharma, A. K. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009885 · Cited by 103 · see citing works
Lim, S. C. L., Hor, C. P., Tay, K. H., Jelani, A. M., Tan, W. H., Ker, H. B., Chow, T. S., Zaid, M., Cheah, W. K., Lim, H. H., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0189 · Cited by 100 · see citing works
Singh, A. K., Singh, R., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102396 · Cited by 90 · see citing works
Ordoñez, A. A., Bullen, C. K., Villabona-Rueda, A. F., Thompson, E. A., Turner, M. L., Merino, V. F., Yan, Y., Kim, J., Davis, S. L., Komm, O. D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03189-z · Cited by 86 · see citing works
Radcliffe, C. V., Palacios, C. F., Azar, M. M., Cohen, E., & Malinis, M. F. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17098 · Cited by 85 · see citing works
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 85 · see citing works
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84 · see citing works
Zheng, B., Green, A. C. A., Tazare, J., Curtis, H. J., Fisher, L., Nab, L., Schultze, A., Mahalingasivam, V., Parker, E. P. K., Hulme, W. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071932 · Cited by 84 · see citing works
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice
Mahalingasivam, V., Su, G., Iwagami, M., Davids, M. R., Wetmore, J. B., & Nitsch, D. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00570-3 · Cited by 83 · see citing works
A molecular understanding of alphavirus entry and antibody protection
Kim, A. S., & Diamond, M. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00825-7 · Cited by 83 · see citing works
Bianchini, F., Crivelli, V., Abernathy, M. E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Pedotti, M., Gasparo, R. D., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade0958 · Cited by 83 · see citing works
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
Perico, N., Cortinovis, M., Suter, F., & Remuzzi, G. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00433-9 · Cited by 80 · see citing works
Siemieniuk, R. A., Bartoszko, J. J., Díaz Martinez, J. P., Kum, E., Qasim, A., Zeraatkar, D., Izcovich, A., Mangala, S., Ge, L., Han, M. A., et al. (2021) · BMJ · doi:10.1136/bmj.n2231 · Cited by 79 · see citing works
ACTIV-3/TICO Bamlanivimab Study Group*, Lundgren, J. D., Grund, B., Barkauskas, C. E., Holland, T. L., Gottlieb, R., Sandkovsky, U., Brown, S. M., Knowlton, K. U., Self, W. H., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3507 · Cited by 78 · see citing works
Hirotsu, Y., Kobayashi, H., Kakizaki, Y., Saito, A., Tsutsui, T., Kawaguchi, M., Shimamura, S., Hata, K., Hanawa, S., Toyama, J., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.001 · Cited by 77 · see citing works
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 76 · see citing works
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.002 · Cited by 75 · see citing works
Therapeutic monoclonal antibodies for COVID-19 management: an update
Chavda, V. P., Prajapati, R., Lathigara, D., Nagar, B., Kukadiya, J., Redwan, E. M. M. M., Uversky, V. N., Kher, M. N., & Patel, R. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2078160 · Cited by 70 · see citing works
An overview on the treatments and prevention against COVID-19
Panahi, Y., Gorabi, A. M., Talaei, S., Beiraghdar, F., Akbarzadeh, A., Tarhriz, V., & Mellatyar, H. (2023) · Virology Journal · doi:10.1186/s12985-023-01973-9 · Cited by 70 · see citing works
Lemaitre, F., Grégoire, M., Monchaud, C., Bouchet, S., Saint–Salvi, B., Polard, É., Benaboud, S., Chouchana, L., Cracowski, J., Drici, M., et al. (2022) · Therapies · doi:10.1016/j.therap.2022.03.005 · Cited by 69 · see citing works
Brüssow, H. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14064 · Cited by 69 · see citing works
Dougan, M. L., Azizad, M., Chen, P., Feldman, B., Frieman, M. B., Igbinadolor, A., Kumar, P. N., Morris, J., Potts, J., Baracco, L., et al. (2022) · medRxiv · doi:10.1101/2022.03.10.22272100 · Cited by 69 · see citing works
COVID-19 Therapeutics for Nonhospitalized Patients
Gandhi, R. T., Malani, P., & del Rı́o, C. (2022) · JAMA · doi:10.1001/jama.2022.0335 · Cited by 67 · see citing works
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Johnson, M. G., Puenpatom, A., Moncada, P. A., Burgess, L. J., Duke, E. R., Ohmagari, N., Wolf, T., Bassetti, M., Bhagani, S., Ghosn, J., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0729 · Cited by 67 · see citing works
Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options
Pelle, M. C., Zaffina, I., Lucà, S., Forte, V., Trapanese, V., Melina, M., Giofrè, F., & Arturi, F. (2022) · Life · doi:10.3390/life12101605 · Cited by 67 · see citing works
Mesenchymal stem cell treatment for COVID-19
Xu, R., Feng, Z., & Wang, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103920 · Cited by 66 · see citing works
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64 · see citing works
Pharmacological treatment of COVID-19: an opinion paper
García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., Guillén, S. M., Rodríguez‐Artalejo, F., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/158.2021 · Cited by 62 · see citing works
Galvani, A. P., Parpia, A. S., Pandey, A., Sah, P., Colon, K., Friedman, G. C., Campbell, T., Kahn, J. G., Singer, B. H., & Fitzpatrick, M. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200536119 · Cited by 62 · see citing works
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A., Luck, M. I., Tian, R., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.003 · Cited by 62 · see citing works
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa
Simonis, A., Kreer, C., Albus, A., Rox, K., Yuan, B., Holzmann, D., Wilms, J. A., Zuber, S., Kottege, L., Winter, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.10.002 · Cited by 62 · see citing works
Bruel, T., Stéfic, K., Nguyen, Y., Toniutti, D., Staropoli, I., Porrot, F., Guivel‐Benhassine, F., Bolland, W., Planas, D., Hadjadj, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100850 · Cited by 60 · see citing works
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
Ragonnet‐Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37826-w · Cited by 60 · see citing works
Haggenburg, S., Lissenberg-Witte, B. I., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., de Rooij, D. M., van Meerloo, J., Cloos, J. J., Kootstra, N. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006917 · Cited by 59 · see citing works
ACTIV-3/TICO Study Group, Rogers, A. J., Wentworth, D. N., Phillips, A. N., Shaw‐Saliba, K., Dewar, R. L., Aggarwal, N. R., Babiker, A. G., Chang, W., Dharan, N. J., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0924 · Cited by 59 · see citing works
Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M. C., Fernandez, M. L. O., Alvisi, M. F., Simone, I. D., Rulli, E., Nobili, A., Casalini, G., et al. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106516 · Cited by 57 · see citing works
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
Touret, F., Baronti, C., Bouzidi, H. S., & de Lamballerie, X. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-08559-5 · Cited by 57 · see citing works
Bell, S., Campbell, J., Lambourg, E., Watters, C., O’Neil, M., Almond, A., Buck, K., Carr, E. J., Clark, L., Cousland, Z., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022010046 · Cited by 56 · see citing works
Heo, Y. (2022) · Drugs · doi:10.1007/s40265-022-01690-7 · Cited by 56 · see citing works
Diagnosis and management of covid-19 in pregnancy
Nana, M., Hodson, K. K., Lucas, N., Camporota, L., Knight, M., & Nelson‐Piercy, C. (2022) · BMJ · doi:10.1136/bmj-2021-069739 · Cited by 56 · see citing works
Abebe, E., & Dejenie, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 51 · see citing works
- Authors
- Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
- Affiliations
- William Osler Health System (CA)
- From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
- Hospital de Clínicas de Porto Alegre (BR)
- The University of Texas at Austin (US)
- VIR Biotechnology (United States) (US)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of Washington (US)
- Corresponding author
- Shapiro, Adrienne E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-18
- Volume
- 385
- Issue
- 21
- Pages
- 1941-1950
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3208080692
- Cited by
- 1,086
- References
- 25
- Citations by year
- 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62 · 2020: 4 · 2012: 1
- FWCI
- 78.13
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
- MeSH terms
- SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
